Birgit C. P. Koch

6.4k total citations · 1 hit paper
272 papers, 4.4k citations indexed

About

Birgit C. P. Koch is a scholar working on Pharmacology, Pediatrics, Perinatology and Child Health and Epidemiology. According to data from OpenAlex, Birgit C. P. Koch has authored 272 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Pharmacology, 75 papers in Pediatrics, Perinatology and Child Health and 53 papers in Epidemiology. Recurrent topics in Birgit C. P. Koch's work include Antibiotics Pharmacokinetics and Efficacy (87 papers), Pharmaceutical studies and practices (37 papers) and Pharmacological Effects and Toxicity Studies (30 papers). Birgit C. P. Koch is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (87 papers), Pharmaceutical studies and practices (37 papers) and Pharmacological Effects and Toxicity Studies (30 papers). Birgit C. P. Koch collaborates with scholars based in Netherlands, Germany and United States. Birgit C. P. Koch's co-authors include Teun van Gelder, Brenda C. M. de Winter, Johan W. Mouton, Anouk E. Muller, Soma Bahmany, Alan Abdulla, Jan‐Willem C. Alffenaar, J.E. Nagtegaal, Rixt A. Wijma and Bart C.H. van der Nagel and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Birgit C. P. Koch

251 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

From Therapeutic Drug Monitoring to Model‐Informed Precision Dosing for Antibiotics

2021 180 citations Birgit C. P. Koch, Iris K. Minichmayr et al. profile →

Peers

Countries citing papers authored by Birgit C. P. Koch

Since Specialization

Citations

This map shows the geographic impact of Birgit C. P. Koch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Birgit C. P. Koch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Birgit C. P. Koch more than expected).

Fields of papers citing papers by Birgit C. P. Koch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Birgit C. P. Koch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Birgit C. P. Koch. The network helps show where Birgit C. P. Koch may publish in the future.

Co-authorship network of co-authors of Birgit C. P. Koch

This figure shows the co-authorship network connecting the top 25 collaborators of Birgit C. P. Koch. A scholar is included among the top collaborators of Birgit C. P. Koch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Birgit C. P. Koch. Birgit C. P. Koch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Drug release from docetaxel-entrapped core-crosslinked polymeric micelles: A population pharmacokinetic modelling approach based on clinical data 2025 ·Biomedicine & Pharmacotherapy ·(unknown), Stijn L.W. Koolen, (unknown), Cristianne J.F. Rijcken, (unknown), Ruben A.G. van Eerden, Florence Atrafi, (unknown), C. Willemien Menke‐van der Houven van Oordt, Birgit C. P. Koch, Ron H.J. Mathijssen, (unknown), (unknown)	1
2	Prediction of Vancomycin Area Under the Curve With Trough Concentrations Only: Performance Evaluation of Pediatric Population Pharmacokinetic Models 2025 ·The Journal of Infectious Diseases ·(unknown), (unknown), Robert B. Flint, Enno D. Wildschut, Birgit C. P. Koch, Brenda C. M. de Winter, Alan Abdulla	1
3	Dose individualisation of antibiotics in critically ill patients with inflammation: A narrative review 2025 ·British Journal of Clinical Pharmacology ·Sarah Dräger, Iris K. Minichmayr, Narges Alipanah, Erin F. Barreto, Lieuwe D. J. Bos, Lucas M. Fleuren, Nicole Hunfeld, (unknown), Sophie L. Stocker, João Paulo Telles, Antoni Torres, Birgit C. P. Koch, Henrik Endeman	0
4	Leveraging Clinical Data to Enhance the Performance Evaluation of Ceftriaxone Population Pharmacokinetic Models in Children 2025 ·Clinical Pharmacokinetics ·(unknown), (unknown), Alan Abdulla, Enno D. Wildschut, Birgit C. P. Koch, Matthijs de Hoog	0
5	Pharmacokinetics of betamethasone in pre‐eclampsia: An in vivo and ex vivo study 2025 ·British Journal of Clinical Pharmacology ·Sam Schoenmakers, (unknown), (unknown), Michelle Broekhuizen, (unknown), A.H. Jan Danser, Irwin Reiss, Karel Allegaert, Sjoerd A.A. van den Berg, Bertrand D. van Zelst, Ron HN van Schaik, Philip DeKoninck, (unknown), (unknown), Sinno H. P. Simons, Birgit C. P. Koch	0
6	Clinical implications of nintedanib pharmacokinetics in patients with pulmonary fibrosis 2024 ·Biomedicine & Pharmacotherapy ·(unknown), (unknown), (unknown), (unknown), (unknown), Birgit C. P. Koch, Marlies Wijsenbeek, Stijn L.W. Koolen, Ron H.J. Mathijssen, G. Veerman	0
7	Higher doses of fluconazole are needed to ensure target attainment in critically ill adults on continuous Veno-venous hemodialysis 2024 ·Journal of Critical Care ·(unknown), (unknown), (unknown), (unknown), Birgit C. P. Koch, (unknown), (unknown), Nicole Hunfeld	0
8	Dosing of Convalescent Plasma and Hyperimmune Anti-SARS-CoV-2 Immunoglobulins: A Phase I/II Dose-Finding Study 2024 ·Clinical Pharmacokinetics ·(unknown), (unknown), Francis Swaneveld, Ilona Kleine Budde, Corine H. GeurtsvanKessel, Birgit C. P. Koch, Bart Rijnders	1
9	Population pharmacokinetics of intraperitoneal irinotecan and SN‐38 in patients with peritoneal metastases from colorectal origin 2024 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), (unknown), (unknown), Ruben A.G. van Eerden, Nadine L. de Boer, (unknown), Jacobus W. A. Burger, Ron H.J. Mathijssen, Birgit C. P. Koch, Stijn L.W. Koolen	2
10	Clinical Experience with Off-Label Intrathecal Administration of Selected Antibiotics in Adults: An Overview with Pharmacometric Considerations 2023 ·Antibiotics ·Anouk E. Muller, Peter Van de Vliet, Birgit C. P. Koch	3
11	Pentoxifylline as a therapeutic option for pre‐eclampsia: a study on its placental effects 2022 ·British Journal of Pharmacology ·Michelle Broekhuizen, René de Vries, (unknown), Willem A. Dik, Sam Schoenmakers, Birgit C. P. Koch, Daphne Merkus, Irwin Reiss, A.H. Jan Danser, Sinno H. P. Simons, (unknown)	8
12	Omeprazole Administration in Preterm Preeclampsia: a Randomized Controlled Trial to Study Its Effect on sFlt-1 (Soluble Fms-Like Tyrosine Kinase-1), PlGF (Placental Growth Factor), and ET-1 (Endothelin-1) 2022 ·Hypertension ·(unknown), (unknown), Langeza Saleh, Michelle Broekhuizen, Daan Nieboer, (unknown), Sam Schoenmakers, (unknown), Birgit C. P. Koch, Henk Russcher, Sjoerd A.A. van den Berg, Anton H. van den Meiracker, W. Edward Visser, A.H. Jan Danser	12
13	Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors 2021 ·Journal for ImmunoTherapy of Cancer ·Daan P. Hurkmans, (unknown), Karlijn de Joode, (unknown), Edwin A. Basak, Annemarie Wijkhuijs, Markus Joerger, Reno Debets, Birgit C. P. Koch, Cor H. van der Leest, Marco W.J. Schreurs, Astrid A.M. van der Veldt, Joachim G.J.V. Aerts, Ron H.J. Mathijssen, Stijn L.W. Koolen	15
14	Sufentanil Disposition and Pharmacokinetic Model-Based Dosage Regimen for Sufentanil in Ventilated Full-Term Neonates 2021 ·Pharmacology ·Pavla Pokorná, Martin Šíma, Birgit C. P. Koch, Dick Tibboel, Ondřej Slanař	6
15	Understanding the association between sleep, shift work and COVID‐19 vaccine immune response efficacy: Protocol of the S‐CORE study 2021 ·Journal of Sleep Research ·(unknown), Gert Jan Lammers, Gijsbertus T. J. van der Horst, Inês Chaves, Rory D. de Vries, Corine H. GeurtsvanKessel, Birgit C. P. Koch, P.H.M. van der Kuy	16
16	Psychotropic drug concentrations and clinical outcomes in children and adolescents: a systematic review 2020 ·Expert Opinion on Drug Safety ·Sanne Kloosterboer, (unknown), Jana Stojanova, Karin Egberts, Manfred Gerlach, Gwen Dieleman, Manon H. J. Hillegers, (unknown), Teun van Gelder, Bram Dierckx, Birgit C. P. Koch	13
17	Urinary antibacterial activity of fosfomycin and nitrofurantoin at registered dosages in healthy volunteers 2019 ·International Journal of Antimicrobial Agents ·Rixt A. Wijma, Angela Huttner, (unknown), Wendy Kloezen, Iain J. Abbott, Anouk E. Muller, Birgit C. P. Koch, Johan W. Mouton	5
18	Opioid responsiveness of nociceptive versus mixed pain in clinical cancer patients 2018 ·European Journal of Cancer ·(unknown), (unknown), Joost van Rosmalen, Birgit C. P. Koch, Carin C.D. van der Rijt, Peter A.E. Sillevis Smitt, Joost L.M. Jongen	9
19	Simultaneous quantification of fentanyl, sufentanil, cefazolin, doxapram and keto‐doxapram in plasma using liquid chromatography–tandem mass spectrometry 2018 ·Biomedical Chromatography ·Robert B. Flint, Soma Bahmany, Bart C.H. van der Nagel, Birgit C. P. Koch	10
20	WIDE - Semantic web for design and engineering 2002 ·Publikationsdatenbank der Fraunhofer-Gesellschaft (Fraunhofer-Gesellschaft) ·Birgit C. P. Koch, (unknown), (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact